Schedule 13D ownership disclosure
BridgeBio Oncology Therapeutics Inc
Common Stock, $0.0001 par value · CUSIP: 107924102
Event date: 2025-08-11
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- BridgeBio Pharma LLCReported CIK 0002076615
Shares: 13,878,554 · Class: 17.5%
- BridgeBio Pharma, Inc.Reported CIK 0001743881
Shares: 13,878,554 · Class: 17.5%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193125-25-182790
- Form type
- SCHEDULE 13D
- Filer
- BridgeBio Oncology Therapeutics, Inc.
- CIK
- CIK 1869105
- Filed
- Aug 18, 2025
- Reporting period
- Aug 11, 2025
- Description
- Schedule 13D beneficial ownership